Goldman Sachs’s Bellerophon Therapeutics, Inc. BLPH Stock Holding History

Goldman Sachs’s Portfolio BLPH Stock Details BLPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-917	Closed	-$8K	–	5499
2019 Q2	$8K	Buy	+917	New	+$8.79K	﹤0.01%	5083
2017 Q2	–	Sell	-5,600	Closed	-$125K	–	7084
2017 Q1	$125K	Buy	+5,600	New	+$88K	﹤0.01%	5967
2015 Q4	–	Sell	-679	Closed	-$53K	–	7475
2015 Q3	$53K	Sell	679 -167	-20%	-$12.9K	﹤0.01%	6771
2015 Q2	$101K	Sell	846 -307	-27%	-$41.7K	﹤0.01%	6603
2015 Q1	$159K	Buy	+1,153	New	+$179K	﹤0.01%	6162

Other funds holding BLPH

NMVA

New Mountain Vantage Advisers New York $4.33B AUM 35.3% 1-Year Est. Return

PCM

Puissance Capital Management New York $17.3M AUM 149.36% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

VMI

VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Goldman Sachs's BLPH Position: Q3 2019 in Review

Goldman Sachs sold out of Bellerophon Therapeutics, Inc. (BLPH) in Q3 2019, closing a stake of 917 shares — an estimated $8K sold.

Goldman Sachs first reported a position in BLPH in Q1 2015 and held it in 5 quarters. The position peaked at $159K in Q1 2015. 23 funds tracked by Wall St. Rank hold BLPH as of Q3 2019.

Goldman Sachs reported no remaining Bellerophon Therapeutics, Inc. position as of Q3 2019 after selling out during the quarter.
Goldman Sachs sold 917 Bellerophon Therapeutics, Inc. shares in Q3 2019, an estimated $8K.
Goldman Sachs first reported a position in Bellerophon Therapeutics, Inc. in Q1 2015 and held it in 5 quarters.
Goldman Sachs's Bellerophon Therapeutics, Inc. position peaked at $159K in Q1 2015.
23 funds tracked by Wall St. Rank held Bellerophon Therapeutics, Inc. as of Q3 2019.

Based on Goldman Sachs's 13F filing for Q3 2019, filed 14 Nov 2019.